ArticleTranslational oncology2026
HSPE1 promotes immune evasion in lung adenocarcinoma by mediating mitochondrial oxidative stress via histone lactylation-mediated SDHA transcriptional activation.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung adenocarcinoma (LUAD) progression relies on the interplay between metabolic reprogramming and epigenetic modifications, yet the glycolysis-mediated histone lactylation is unexplored. This study aims to uncover the mechanism of this regulatory axis in LUAD progression. Bioinformatics analyses identified the enriched pathways of HSPE1 and SDHA. CIBERSORT and xCell algorithms investigated SDHA expression-immune infiltration correlations. qRT-PCR and immunohistochemical analysis revealed elevated histone lactylation in LUAD tissues. Furthermore, exogenous lactate treatment induced H3K18la and elevated SDHA in A549 cells. Chromatin immunoprecipitation assays confirmed the enrichment of H3K18la at the SDHA promoter region, directly regulating its transcriptional activity. Functional experiments demonstrated that SDHA overexpression enhanced cell viability and inhibited apoptosis by promoting oxidative stress (manifested by elevated malondialdehyde levels and altered superoxide dismutase and glutathione levels). Mechanistic investigations further revealed the enrichment of HSPE1 in the glycolysis pathway. HSPE1 overexpression enhanced glycolysis-derived lactate production, increasing H3K18la occupancy at the SDHA promoter, establishing a HSPE1-glycolysis-lactate-H3K18la-SDHA-oxidative stress positive feedback loop to accelerate LUAD progression. SDHA overexpression was negatively correlated with DC infiltration; excessive ROS induced DC cell death, indicating that HSPE1/SDHA axis-mediated oxidative stress may facilitate the immune escape of LUAD cells by impairing DC function. In vivo/in vitro functional assays verified the oncogenic function of this axis. In conclusion, HSPE1 drives the transcriptional activation of SDHA through the glycolysis-H3K18la epigenetic modification, thereby intensifying the oxidative stress microenvironment and promoting LUAD malignant progression. HSPE1-SDHA axis-induced oxidative stress may remodel tumor immune microenvironment via inhibiting DC antigen presentation, supporting combined immunotherapy development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.